Reuters logo
BRIEF-Kura Oncology doses first patient in phase 1 trial of ERK inhibitor KO-947
2017年4月7日 / 中午11点54分 / 5 个月前

BRIEF-Kura Oncology doses first patient in phase 1 trial of ERK inhibitor KO-947

April 7 (Reuters) - Kura Oncology Inc:

* Kura Oncology doses first patient in phase 1 trial of ERK Inhibitor KO-947 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below